Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Over Two Years of Sustained Remission With Olaparib Monotherapy in Stage IV Non-Small Cell Lung Cancer With ATM Mutation: A Case Report.

Cancer reports (Hoboken, N.J.) - 1 Jul 2025

Tang Zhiting, Bi Ran, Idriss Mutasim, Wang Qian, Wang Qi, Ban-Hoefen Makiko

Abstract excerpt

BACKGROUND: Ataxia telangiectasia mutated (ATM) mutations represent the most common homologous recombination deficiency (HRD) mutation in non-small cell lung cancer (NSCLC). However, their therapeutic role in NSCLC has not been established. CASE: Here, we present a case of a 91-year-old male with metastatic NSCLC who progressed on multiple lines of treatment. Next-generation sequencing revealed ATM mutations,...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Ataxia Telangiectasia Mutated Proteins
Share to Carcinoma, Non-Small-Cell Lung

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Lung Neoplasms

Share to Neoplasm Staging

Share to Phthalazines

Share to Piperazines

Share to Poly(ADP-ribose) Polymerase Inhibitors

Share to Remission Induction

Source

Open in PubMed Open full text

Identifiers

PMID: 40622001
DOI: 10.1002/cnr2.70276
PMCID: PMC12231064

Genes

ATM

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Over Two Years of Sustained Remission With Olaparib Monotherapy in Stage IV Non-Small Cell Lung Cancer With ATM Mutation: A Case Report.PMID 40622001Read ↗

Metastatic lung adenocarcinoma with BRCA2 mutation and longstanding disease control on olaparib, developing triple negative breast adenocarcinoma with additional BRCA2 reversion mutation: a case report.Semantic proximity Read ↗

Non-small cell lung cancer cells with deficiencies in homologous recombination genes are sensitive to PARP inhibitors.Semantic proximity Read ↗

Combination of gefitinib and olaparib versus gefitinib alone in EGFR mutant non-small-cell lung cancer (NSCLC): A multicenter, randomized phase II study (GOAL).Semantic proximity Read ↗

Durable response to afatinib rechallenge in a long-term survivor of non-small cell lung cancer harboring EGFR L858R and L747V mutations.Semantic proximity Read ↗

The enrichment of Fanconi anemia/homologous recombination pathway aberrations in ATM/ATR-mutated NSCLC was accompanied by unique molecular features and poor prognosis.Semantic proximity Read ↗

Successful AZD9291 Therapy in Advanced Non-Small Cell Lung Cancer after Failure of HM61713.Semantic proximity Read ↗

Complete Remission to Afatinib in a Patient Harboring a Novel Epidermal Growth Factor Mutation in De Novo Small-Cell Lung Cancer: A Case Report: Clinical Lung Cancer.Semantic proximity Read ↗

Overall Survival With Maintenance Olaparib at a 7-Year Follow-Up in Patients With Newly Diagnosed Advanced Ovarian Cancer and a BRCA Mutation: The SOLO1/GOG 3004 Trial.Semantic proximity Read ↗

A never-smoker lung adenocarcinoma patient with a MET exon 14 mutation (D1028N) and a rapid partial response after crizotinib.Semantic proximity Read ↗

A Prospective Phase II Single-arm Study of Niraparib Plus Dostarlimab in Patients With Advanced Non-small-cell Lung Cancer and/or Malignant Pleural Mesothelioma, Positive for PD-L1 Expression and Germline or Somatic Mutations in the DNA Repair Genes: Rationale and Study Design.Semantic proximity Read ↗

Long-term Survival With Afatinib in a Patient With Lung Adenocarcinoma Harboring Double Uncommon EGFR L861Q and G719X Mutations.Semantic proximity Read ↗

The Combination of the PARP Inhibitor Olaparib and the WEE1 Inhibitor AZD1775 as a New Therapeutic Option for Small Cell Lung CancerSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.